The Global Manufacturing and Industrialisation Summit Joins Germany in the Fight Against Climate Change
- GMIS partners with German organisations to launch ‘The Green Chain Initiative’, a multi-stakeholder effort to develop new renewable energy global value chains
- The Initiative will link developed and developing countries by combining a crowd-sourcing platform with blockchain technologies to support the green agenda
- Mass-scale decarbonisation of industry is essential in tackling climate change while also delivering sustainable industrial development
- Initiative was endorsed by UNIDO and German organisations including BDI, DIHK, VDMA, ZVEI and GHORFA
- The Initiative will promote clean energy, green products, and socially-responsible investments to drive carbon-neutrality
The Global Manufacturing and Industrialisation Summit (GMIS) today announced an unconventional global initiative, in partnership with leading German associations, to accelerate the decarbonisation of industry and the development of renewable energy projects supporting the global green agenda as well as Germany’s National Hydrogen Strategy. The ‘Green Chain Initiative’ aims to develop new, renewable energy value chains by combining a crowd-sourcing platform with blockchain technologies to promote inclusive and sustainable industrial development.
Inspired by Germany's leadership in driving clean technologies, and its ambitions for a net-zero carbon world, the pioneering ‘Green Chain Initiative’ was announced by Badr Al-Olama, Head of the GMIS Organising Committee, during the Virtual Edition of the Global Manufacturing and Industrialisation Summit (#GMIS2020). Also present during the announcement were Holger Lösch, Deputy Director General and member of the Executive Board of the Federation of German Industries (BDI), Dr. Volker Treier, Deputy Chief Executive Officer of the Association of German Chambers of Commerce and Industry (DIHK), and Dr Hiroshi Kuniyoshi, Deputy Director General and Managing Director, External Relations and Policy Research of the United Nations Industrial Development Organization.
Al-Olama said the pause in day-to-day human activities over the past few months highlighted just how big of an impact humanity was having on the planet. During lockdowns imposed by various governments to stall the spread of the pandemic, pollution levels in urbanised areas dropped dramatically, resulting in cleaner air in cities around the world.
“Taking the events of the past few months into consideration, we wanted to initiate a legacy that can truly make a difference to our world, ensuring green energy to make green products that can be bought using green currencies,” Al-Olama said. “Hence, I'm proud to formally announce, on behalf of the Organising Committee for #GMIS2020, our new legacy initiative called The Green Chain. The Green Chain Initiative will crowdsource renewable energy projects that will use 4IR technologies to create the outcome of a greener planet for all.
“This initiative truly converges the interests of governments – by providing new sources of green energy, with the interests of industries – that will produce green products by decarbonising their manufacturing facilities, with the interests of consumers – who are able to opt for green crypto-currencies to purchase these products. What is also unique about this initiative is that it includes all countries of the world, not just those with fossil fuel resources, and not just those with renewable energy. In that sense, what better partner for us to adopt and co-lead this initiative than Germany, a country with a proven track record in launching strategies for carbon neutrality.”
To define the concept and shape the objectives of the Initiative, GMIS formed a working group, comprised of leading industrial experts representing the United Nations Industrial Development Organisation (UNIDO), the Federation of German Industries (BDI), the Association of German Chambers of Commerce and Industry (DIHK), the Association of German Engineers (VDMA), the German Electrical, Electronic Manufacturers Association (ZVEI), and the Arab-German Chamber of Commerce and Industry (GHORFA).
Innovation to tackle climate change
Volker Treier said tackling climate change remains one of the major issues facing humanity. However, he said there needs to be a common understanding at a global level or at least a European understanding, to fully address the challenge.
“Right now Germany is a good role model, but we need a European approach in order to maintain competitiveness because we are a highly industrialised country,” he said. “The problem is that policy makers are acting more or less on a national basis, and not on a European or a multilateral fundament.”
Dr. Hiroshi Kuniyoshi pointed out that the International Energy Agency (IEA) has predicted that CO2 emissions in 2020 would fall by 8% compared to 2019 levels. Despite the massive slow-down in economic activities, this is still far below what is required to meet the targets of the Paris Agreement.
“We need to introduce something more, and that is innovation,” he said. “We need to introduce innovative technologies, including renewable energy and energy conservation technologies. Manufacturing and industry needs to help the whole world by actively working on that direction and we all need to work together to achieve this.”
Lösch said reductions in CO2 over the past few months had come at a very high price in terms of the disruption to people’s livelihoods and that the fallout from the coronavirus will likely continue for years to come. “To protect the climate we have to change everything about the way we are doing business, and therefore, we really have to focus on enormously intelligent and efficient ways to tackle this problem.”
Defossilsing the energy system globally is the main priority, he said, followed by major investments in energy efficiency, and followed by the ability to couple sectors intelligently, highlighting the example of getting the mobility sector to defossilise in combination with the energy sector. “All of this is very demanding, but it can be done by technology and by innovation. And this is, of course, a core competence of industry,” Lösch said.
Badr Al Olama, Head of the Organising Committee of the Global Manufacturing and Industrialisation, added: “#GMIS2020 was originally scheduled to be held in Germany alongside Hannover Messe in April before we shifted to our first Virtual Summit in line with COVID19 concerns. I am truly excited to advance our collaboration with Germany and launch the Green Chain Initiative. Together with Germany, we look forward to accelerating the decarbonisation of industry, through the transfer of knowledge and best practices, and addressing the challenges of climate change. The Green Chain Initiative will truly leave a legacy following #GMIS2020.”
Under the theme – Glocalisation: Towards Sustainable and Inclusive Global Value Chains, the #GMIS2020 Virtual Summit took place on September 4-5 and gathered a cross-section of close to 100 global leaders from the public and private sector participating across more than 20 virtual sessions. The first day of the Virtual Summit featured a series of keynote opening speeches and German-focused discussion on critical topics including Germany’s ‘Marshall Plan with Africa’ and the ‘Global Hydrogen Economy’. There was also a series of working group sessions which involved high-level representatives from industry and world-renowned organisations to discuss the development of a number of new initiatives the Summit plans to launch in the near future.
The second day of the Summit featured a series of keynote addresses and panel sessions involving Heads of State, Ministers, and thought-leaders from some of the world’s leading organisations. Discussions focused on the major issues facing the manufacturing sector and will explore how the adoption of 4IR technologies, localising production capabilities and capacity building, and spreading inclusive and sustainable development will all be critical to the future of global value chains.
To learn more about GMIS, please visit https://gmisummit.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom